Natural history study for MPS IIIC
Part of Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This study follows people with MPS IIIC (Sanfilippo syndrome type C) over time to understand how the disease changes. It does not test a new treatment, but helps researchers learn more about the condition, which could lead to better care in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must be between 1 and 25 years old.
- You must have a confirmed diagnosis of MPS IIIC (Sanfilippo syndrome type C).
- You need to be able to eat or drink by mouth and walk (with or without help).
- You must have health insurance and a smartphone or tablet with internet.
- A caregiver must be willing to help with study visits at home.
- You must speak English, Spanish, French, German, or Portuguese as your first language.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with Sanfilippo syndrome type C to better understand how the disease changes over time. It does not appear to test a new medicine; instead, it collects health and development information that can help future treatments.
This study follows people with MPS, a rare genetic condition, to learn more about the disease over time. If you have a confirmed MPS diagnosis, you may be able to join.
This trial tests a new medicine called GC1130A for children with Sanfilippo syndrome type A (MPS IIIA). The goal is to see if it is safe and if it might help with symptoms.
This trial tests a gene-transfer treatment (delivered into the spinal fluid) for children with MPS IIIA, a rare genetic condition. It aims to improve or slow down brain and developmental changes caused by a missing enzyme.
This follow-up study looks at how a past gene therapy treatment (UX111) is affecting you over time. It mainly involves continued visits and safety checks, and it helps researchers understand long-term benefits and risks.
This trial enrolls people with mucopolysaccharidosis type VII (MPS VII) to track their health over time. It may help your care team better understand how the condition behaves and how monitoring should be done.
Hear when a new Sanfilippo Syndrome Type C trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.